Cargando…
The Icelandic founder mutation BRCA2 999del5: analysis of expression
INTRODUCTION: A founder mutation in the BRCA2 gene (BRCA2 999del5) accounts for 7–8% of female breast cancers and for 40% of male breast cancers in Iceland. If expressed, the mutant gene would encode a protein consisting of the first 256 amino acids of the BRCA2 protein. The purpose of this study wa...
Autores principales: | Mikaelsdottir, Evgenia K, Valgeirsdottir, Sigridur, Eyfjord, Jorunn E, Rafnar, Thorunn |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC468616/ https://www.ncbi.nlm.nih.gov/pubmed/15217494 http://dx.doi.org/10.1186/bcr785 |
Ejemplares similares
-
BRCA2 interacting proteins
por: Vidarsson, H, et al.
Publicado: (2000) -
Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression
por: Stefansson, Olafur A, et al.
Publicado: (2011) -
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
por: Stefansson, Olafur Andri, et al.
Publicado: (2009) -
Correction: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
por: Stefansson, Olafur Andri, et al.
Publicado: (2009) -
Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers
por: Aradottir, Margret, et al.
Publicado: (2014)